ABSTRACT
Purpose AHNAK2 has been reported as tumor promoting protein by mediating tumor cell invasion and metastasis in a variety of malignancies, but the role of AHNAK2 in GC is indistinct.
Methods Immunohistochemistry(IHC)was used to verify in GC tissues, clinical and pathological files were collected to figure out the correlation of AHNAK2 and prognosis in GC patients. GC cell lines were cultured to detect the expression and location of AHNAK2 by westernblot and immunofluorescence. Knockdown AHNAK2 to observe the invasion and metastasis of GC cell. Transcriptome sequencing was performed to explore the potential regulatory mechanism of AHNAK2.
Results IHC results shows that AHNAK2 is upregulated in GC patients compared to normal people, overall survival in highly expressed AHNAK2 is poor,and AHNAK2 expression was positively correlated with lymph node metastasis. The expression of AHNAK2 in tumor cells is higher than in normal cell. Knockdown AHNAK2 decreased the proliferation, invasion, migration ability of GC cells, and increased cell apoptosis. Transcriptome sequencing reveals that AHNAK2 mediates GC progression by regulating Wnt/β-catenin axis.
Conclusion Our findings suggest that AHNAK2 may promote the progression of GC by regulating Wnt/β-catenin signaling pathway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study on human tissues was approved by the Ethics Committee of Ningxia Medical University General Hospital (ethics code: KYLL-2024-0023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Datasets generated and/or analyzed during the current study are available at the National Center for Biotechnology Information in the repository, [https://dataview.ncbi.nlm.nih.gov/object/PRJNA1214896?reviewer=o3idag4aqm507rh0obobeaei4r] ". All data and materials are available in the paper and the supplementary information. Source data are provided with this paper.
https://dataview.ncbi.nlm.nih.gov/object/PRJNA1214896?reviewer=o3idag4aqm507rh0obobeaei4r
